PTC Therapeutics’ AADC deficiency gene therapy granted FDA approval
PTC Therapeutics (PTCT) announced that the FDA accelerated approval of its gene therapy for the treatment of AADC deficiency, the first-ever ...
Reuters16h
US FDA approves PTC Therapeutics' gene therapy for ultra-rare disorder
Nov 13 (Reuters) - The U.S. Food and Drug Administration approved PTC Therapeutics' (PTCT.O), opens new tab gene therapy to ...
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript November 7, 2024 PTC Therapeutics, Inc. beats earnings expectations. Reported EPS is $-1.39, ...
PTC Therapeutics Reports Strong Q3 2024 Performance
PTC Therapeutics ( (PTCT) ) has released its Q3 earnings. Here is a breakdown of the information PTC Therapeutics presented to its investors.
Zacks.com on MSN6d
PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
PTC Therapeutics (PTCT) reported $196.79 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 0.1%. EPS of -$1.39 for the same period compares to -$1.76 a ...
PTC Therapeutics: Q3 Earnings Snapshot
The biopharmaceutical company posted revenue of $196.8 million in the period, also beating Street forecasts. Five analysts surveyed by Zacks expected $173.5 million. PTC Therapeutics expects full-year ...